If you’ve ever watched the litany of gold mining programs on cable TV’s reality TV channels, you’ve seen folks jumping up and down like they have a weasel in…
Chris’ Corner
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks laughed uproariously at the…
In the North American biotech space, you hear a lot of ‘promise’ from companies and their teams. Lots of ‘we’re going to take this to trial’, and a lot…
Aequus Pharmaceuticals (AQS.V), a specialty pharma company with a business model of acquiring and re-platforming existing approved biotech and health products to appeal to a wider market, has announced…
Just a few months since announcing they were merging with Askott Entertainment, a deal that brought casino gaming and daily fantasy sports access to FansUnite’s (FANS.C) sports betting platform,…
Let’s take a step back. Take a breath. Maybe meditate or toss back a tequila shot. Okay, we good for a chat? It’s been a rough few years for…
When we first talked about Tocvan Ventures (TOC.C) back in June, it was selling for around $0.15 and nobody was really talking about it. In certain markets, hype is…
If you’ve been paying attention over the last few years, you’ve seen a few nice runs for companies engaged in the security/military space. Patriot One (PAT.C) has done nicely…
For the last several years, a lot of stories I’ve written on this site have been about promise. The promise of something better, cheaper, with more upside, with less…
UK-based commodities reporter Pratima Desai appears to have either been a useful idiot or a willing accomplice to a stock price run and subsequent insider sell-off of Canadian smallcap…